Molecular mechanisms of docetaxel resistance in prostate cancer

Abstract

Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the clinical utility of DTX is compromised when primary and acquired resistance are encountered. Therefore, a more thorough understanding of DTX resistance mechanisms may potentially improve survival in patients with CRPC. This review focuses on DTX and discusses its mechanisms of resistance. We outline the involvement of tubulin alterations, androgen receptor (AR) signaling/AR variants, ERG rearrangements, drug efflux/influx, cancer stem cells, centrosome clustering, and phosphoinositide 3-kinase/AKT signaling in mediating DTX resistance. Furthermore, potential biomarkers for DTX treatment and therapeutic strategies to circumvent DTX resistance are reviewed.

Keywords

Prostate cancer / docetaxel / drug resistant cancer / biomarker

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Cornford P,Bolla M,De Santis M.EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer..Eur Urol2017;71:630-42

[3] Karantanos T,Tombal B,Montironi R.Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level..Eur Urol2015;67:470-9 PMCID:PMC5301306

[4] Petrylak DP,Hussain MH,Jones JA.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer..N Engl J Med2004;351:1513-20

[5] Tannock IF,Berry WR,Pluzanska A.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer..N Engl J Med2004;351:1502-12

[6] Kraus LA,Schmid SM,Waud WR.The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation..Invest New Drugs2003;21:259-68

[7] Kroon J,Cho NJ,van der Pluijm G.Improving taxane-based chemotherapy in castration-resistant prostate cancer..Trends Pharmacol Sci2016;37:451-62

[8] Gan L,Wang Y,Bohrer L.Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer..Cancer Res2009;69:8386-94 PMCID:PMC2783542

[9] Mistry SJ.New paradigms in microtubule-mediated endocrine signaling in prostate cancer..Mol Cancer Ther2013;12:555-66

[10] James ND,Clarke NW,Dearnaley DP.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial..Lancet2016;387:1163-77 PMCID:PMC4800035

[11] Kyriakopoulos CE,Carducci MA,Jarrard DF.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial..J Clin Oncol2018;36:1080-7 PMCID:PMC5891129

[12] Bumbaca B.Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies..Acta Pharm Sin B2018;8:518-29 PMCID:PMC6089846

[13] Goodson HV.Microtubules and microtubule-associated proteins..Cold Spring Harb Perspect Biol2018;10:a022608 PMCID:PMC5983186

[14] Lopata MA.In vivo microtubules are copolymers of available beta-tubulin isotypes: localization of each of six vertebrate beta-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens..J Cell Biol1987;105:1707-20 PMCID:PMC2114651

[15] Kanakkanthara A,Northcote PT,Miller JH.Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding..Curr Cancer Drug Targets2014;14:79-90

[16] Hara T,Nishiwaki M,Araki H.A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line..Cell Biol Int2010;34:177-84

[17] Ploussard G,Maillé P,Sirab N.Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy..Cancer Res2010;70:9253-64 PMCID:PMC3290526

[18] Sekino Y,Kawaguchi T,Goto K.TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer..Int J Mol Sci2019;20:3936 PMCID:PMC6719236

[19] Maahs L,Gupta N,Barrack ER.Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer..PLoS One2019;14:e0222510 PMCID:PMC6816559

[20] Weingarten MD,Hwo SY.A protein factor essential for microtubule assembly..Proc Natl Acad Sci U S A1975;72:1858-62 PMCID:PMC432646

[21] Yang J,Liu W,Wei Z.Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines..Res Rep Urol2017;9:71-7 PMCID:PMC5428793

[22] Hotte SJ.Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins..Future Oncol2017;13:369-79

[23] Yang CH.Taxol((R)): the first microtubule stabilizing agent..Int J Mol Sci2017;18:1733 PMCID:PMC5578123

[24] Gjyrezi A,Voznesensky O,Calagua C.Taxane resistance in prostate cancer is mediated by decreased drug-target engagement..J Clin Invest2020;130:3287-98 PMCID:PMC7259995

[25] Darshan MS,Thadani-Mulero M,Escuin D.Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer..Cancer Res2011;71:6019-29 PMCID:PMC3354631

[26] Kuroda K,Kim S,Navarro V.Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy..Prostate2009;69:1579-85

[27] Komura K,Hinohara K,Wang X.Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression..Proc Natl Acad Sci U S A2016;113:6259-64 PMCID:PMC4896695

[28] Sekino Y,Goto K,Shigematsu Y.Transcribed ultraconserved region Uc.63+ promotes resistance to docetaxel through regulation of androgen receptor signaling in prostate cancer..Oncotarget2017;8:94259-70 PMCID:PMC5706872

[29] Antonarakis ES,Galletti G,Ballman K.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer..J Clin Oncol2017;35:3181-8 PMCID:PMC5791829

[30] Conteduca V,Romero-Laorden N,Salvi S.Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer..Eur Urol2019;75:368-73 PMCID:PMC6377278

[31] Hu R,Mostaghel EA,Gurel M.Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer..Cancer Res2012;72:3457-62 PMCID:PMC3415705

[32] Zhang G,Li J,Alvarez X.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents..Oncotarget2015;6:23358-71 PMCID:PMC4695123

[33] Thadani-Mulero M,Giannakakou P.Androgen receptor on the move: boarding the microtubule expressway to the nucleus..Cancer Res2012;72:4611-5 PMCID:PMC3448065

[34] Shimizu Y,Kato M,Takeyama Y.Androgen receptor splice variant 7 drives the growth of castration resistant prostate cancer without being involved in the efficacy of taxane chemotherapy..J Clin Med2018;7:444 PMCID:PMC6262607

[35] Lombard AP,Cucchiara V,Armstrong CM.Intra versus inter cross-resistance determines treatment sequence between taxane and AR-targeting therapies in advanced prostate cancer..Mol Cancer Ther2018;17:2197-205 PMCID:PMC6168406

[36] Shiota M,Yamamoto Y,Imada K.Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants..Cancer Sci2018;109:3224-34 PMCID:PMC6172053

[37] Tagawa ST,Gjyrezi A,Kim S.Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY..Clin Cancer Res2019;25:1880-8 PMCID:PMC6432911

[38] Marín-Aguilera M,Reig Ò,Verma AK.Androgen receptor and its splicing variant 7 expression in peripheral blood mononuclear cells and in circulating tumor cells in metastatic castration-resistant prostate cancer..Cells2020;9:203 PMCID:PMC7016895

[39] Antonarakis ES,Luber B,Chen Y.Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer..JAMA Oncol2015;1:582-91 PMCID:PMC4537351

[40] Nimir M,Jeffreys SA,Young F.Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes..Cells2019;8:688 PMCID:PMC6678978

[41] Tomlins SA,Perner S,Mehra R.Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer..Science2005;310:644-8

[42] Brenner JC,Li Y,Cao Q.Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer..Cancer Cell2011;19:664-78 PMCID:PMC3113473

[43] Tsourlakis MC,Grupp K,Steurer S.βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion..Am J Pathol2014;184:609-17

[44] Galletti G,Beltran H,Miguel Mosquera J.ERG induces taxane resistance in castration-resistant prostate cancer..Nat Commun2014;5:5548 PMCID:PMC4244604

[45] Shao L,Yan G,Ozpolat B.Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer..Prostate2020;80:65-73 PMCID:PMC6925833

[46] Reig O,Carrera G,Pare L.TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer..Eur Urol2016;70:709-13

[47] Marin-Aguilera M,Mila-Guasch M,Domenech M.The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer..Int J Cancer2019;145:1970-81

[48] Sánchez C,Contreras HR,McCubrey JA.Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs..Prostate2009;69:1448-59

[49] Sánchez C,Contreras HR,Cabezas J.Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins..Prostate2011;71:1810-7

[50] de Morrée E,Aghai A,de Bruijn P.Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation..Prostate2016;76:927-36

[51] Wang B,Sun EI,Saier MH Jr.Membrane porters of ATP-binding cassette transport systems are polyphyletic..J Membr Biol2009;231:1-10

[52] Davidson AL,Orelle C.Structure, function, and evolution of bacterial ATP-binding cassette systems..Microbiol Mol Biol Rev2008;72:317-64 PMCID:PMC2415747

[53] Martin SK.Exploitation of the androgen receptor to overcome taxane resistance in advanced prostate cancer..Adv Cancer Res2015;127:123-58

[54] Sissung TM,Deeken J,Aragon-Ching J.ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel..Clin Cancer Res2008;14:4543-9 PMCID:PMC2723795

[55] Lombard AP,Armstrong CM,Gu X.ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer..Mol Cancer Ther2017;16:2257-66 PMCID:PMC5628132

[56] Wang Y,Chen CZ,Evans CP.Therapeutic targeting of MDR1 expression by RORγ antagonists resensitizes cross-resistant CRPC to taxane via coordinated induction of cell death programs..Mol Cancer Ther2020;19:364-74

[57] Kato T,Kameyama K,Fujita Y.Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer..Urol Oncol2015;33:385.e15-20

[58] Hagenbuch B.Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties..Pflugers Arch2004;447:653-65

[59] Smith NF,Desai N,Sparreboom A.Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel..Cancer Biol Ther2005;4:815-8

[60] de Morrée ES,van Soest RJ,de Ridder CM.Loss of SLCO1B3 drives taxane resistance in prostate cancer..Br J Cancer2016;115:674-81 PMCID:PMC5023781

[61] Pressler H,Venzon D,Figg WD.Expression of OATP family members in hormone-related cancers: potential markers of progression..PLoS One2011;6:e20372 PMCID:PMC3098289

[62] Alsinnawi M,Bianchi-Frias D,Cho E.Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy..Prostate Cancer Prostatic Dis2019;22:560-8 PMCID:PMC6752995

[63] Skvortsov S,Tang DG.Concise review: prostate cancer stem cells: current understanding..Stem Cells2018;36:1457-74

[64] Castillo V,Huidobro C,Castellon EA.Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer..Int J Oncol2014;45:985-94 PMCID:PMC4121425

[65] Collins AT,Hyde C,Maitland NJ.Prospective identification of tumorigenic prostate cancer stem cells..Cancer Res2005;65:10946-51

[66] Burger PE,Xiong X,Salm SN.High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells..Stem Cells2009;27:2220-8 PMCID:PMC2887284

[67] van den Hoogen C,Cheung H,Lippitt JM.High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer..Cancer Res2010;70:5163-73

[68] Castellón EA,Lillo J,Contreras HR.Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis..Biol Res2012;45:297-305

[69] Lai CJ,Liao WY,Wang HD.CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of Hippo-Yap signaling..Cells2019;8:295 PMCID:PMC6523775

[70] Marin-Aguilera M,Reig O,Fernandez PL.Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer..Mol Cancer Ther2014;13:1270-84

[71] Domingo-Domenech J,Rodriguez-Bravo V,Quinn SA.Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells..Cancer Cell2012;22:373-88 PMCID:PMC5989708

[72] Mittal K,Kaur R,Gupta MV.Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer..Br J Cancer2017;116:1186-94 PMCID:PMC5418452

[73] Salem O.The hippo pathway in prostate cancer..Cells2019;8:370 PMCID:PMC6523349

[74] Gruber M,Culig Z.The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells..Prostate2020;80:267-73 PMCID:PMC7003856

[75] Trerotola M,Goel HL,Alberti S.CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells..Am J Transl Res2010;2:135-44 PMCID:PMC2855629

[76] Kanwal R,Walker E.Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics..Cancer Lett2018;430:25-33

[77] Tan H,Liu Y,Cao W.CD133 antibody targeted delivery of gold nanostars loading IR820 and docetaxel for multimodal imaging and near-infrared photodynamic/photothermal/chemotherapy against castration resistant prostate cancer..Nanomedicine2020;27:102192

[78] Carceles-Cordon M,Gomella L,Rodriguez-Bravo V.Cellular rewiring in lethal prostate cancer: the architect of drug resistance..Nat Rev Urol2020;17:292-307 PMCID:PMC7218925

[79] Qiu S,Bao Y,Tu X.Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition..Anticancer Drugs2018;29:871-9

[80] Liu C,Bi L,Zhou B.NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells..Mol Cell Biochem2014;393:265-70

[81] Mimeault M,Vankatraman G,Henichart JP.Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells..Mol Cancer Ther2007;6:967-78

[82] Mimeault M,Henichart JP,Batra SK.Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells..Mol Cancer Ther2010;9:617-30 PMCID:PMC3228252

[83] Cui D,Keller JM,Xia S.Notch pathway inhibition using PF-03084014, a γ-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer..Clin Cancer Res2015;21:4619-29 PMCID:PMC4609279

[84] Mimeault M,Muniyan S,Johansson SL.Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer..Oncotarget2015;6:3887-903 PMCID:PMC4414161

[85] Rath O.Kinesins and cancer..Nat Rev Cancer2012;12:527-39

[86] Vale RD.The molecular motor toolbox for intracellular transport..Cell2003;112:467-80

[87] Kapitein LC,Kwok BH,Kapoor TM.The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks..Nature2005;435:114-8

[88] Beer TM,Synold TW,Vasist LS.Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes..Clin Genitourin Cancer2008;6:103-9

[89] Wiltshire C,Stockley J,Doyle B.Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition..Mol Cancer Ther2010;9:1730-9

[90] Kwon M,Chandhok NS,Azioune A.Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes..Genes Dev2008;22:2189-203 PMCID:PMC2518815

[91] Sekino Y,Shigematsu Y,Sakamoto N.KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer..Urol Oncol2017;35:31.e13-20

[92] Sekino Y,Koike Y,Sakamoto N.KIFC1 inhibitor CW069 induces apoptosis and reverses resistance to docetaxel in prostate cancer..J Clin Med2019;8:225 PMCID:PMC6407017

[93] Yang J,Ma X,Peng Y.Targeting PI3K in cancer: mechanisms and advances in clinical trials..Mol Cancer2019;18:26 PMCID:PMC6379961

[94] Malik SN,Ghosh PM,Prihoda T.Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer..Clin Cancer Res2002;8:1168-71

[95] Carver BS,Wongvipat J,Chen Y.Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer..Cancer Cell2011;19:575-86 PMCID:PMC3142785

[96] Kosaka T,Shirotake S,Kikuchi E.Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer..J Urol2011;185:2376-81

[97] Yasumizu Y,Kosaka T,Kikuchi E.Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer..J Urol2014;191:227-34

[98] Davies BR,Dudley P,Yu DH.Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background..Mol Cancer Ther2012;11:873-87

[99] Crabb SJ,Martin K,Ratcliffe I.ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer..Invest New Drugs2017;35:599-607 PMCID:PMC5613074

[100] Gorin MA,van der Toom E,Allaf ME.Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer..Nat Rev Urol2017;14:90-7

[101] Iacovelli R,Schinzari G,Maiorano BA.Biomarkers of response to advanced prostate cancer therapy..Expert Rev Mol Diagn2020;20:195-205

[102] Goldkorn A,Quinn DI,Fink LM.Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer..J Clin Oncol2014;32:1136-42 PMCID:PMC3970171

[103] Vogelzang NJ,Burke JM,Bellmunt J.Circulating tumor cells in a Phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer..Eur Urol2017;71:168-71

[104] Underhill HR,Hellwig S,Daza R.Fragment length of circulating tumor DNA..PLoS Genet2016;12:e1006162 PMCID:PMC4948782

[105] Kienel A,Heidenreich A.cfDNA as a prognostic marker of response to taxane based chemotherapy in patients with prostate cancer..J Urol2015;194:966-71

[106] Mehra N,Sumanasuriya S,Pope L.Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA)..European Urology2018;74:283-91 PMCID:PMC6090941